Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

gemcitabine/tipifarnib

Known as: Gemcitabine/R115777, dFdC/R115777 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
In this randomized, double-blind, placebo-controlled study comparing gemcitabine+tipifarnib (G+t) or gemcitabine+placebo (G+p) in… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Highly Cited
2007
Highly Cited
2007
Zoledronic acid (ZOL) has proved activity in bone metastases from prostate cancer through inhibition of mevalonate pathway and of… Expand
2007
2007
Cross-talk between receptor tyrosine kinases and estrogen receptor is at least partly responsible for the development of acquired… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
Interferon α (IFNα) induces an EGF‐Ras→Raf‐1→Erk dependent survival pathway counteracting apoptosis induced by the cytokine. In… Expand
2007
2007
Cross-talk between receptor tyrosine kinases and estrogen receptor is at least partly responsible for the development of acquired… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2005
2005
The high incidence of activating RAS mutations, coupled with accumulating evidence linking RAS to multiple myeloma (MM… Expand
Highly Cited
2004
Highly Cited
2004
Ras activation is frequently observed in multiple myeloma either by mutation or through interleukin-6 receptor signaling… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
2003
2003
PURPOSE Inhibitors of farnesyltransferase (e.g., R115777) are being developed for therapy and prevention of various cancers. The… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Review
2001
Review
2001
Farnesyltransferase inhibitors represent a new class of agents that target signal transduction pathways responsible for the… Expand